New Treatment Combination Enhances Progression-Free Survival in Metastatic ER-Positive, HER2-Negative Breast Cancer

In a landmark advancement for the treatment of metastatic estrogen-receptor-positive (ER-positive), HER-2-negative breast cancer, new clinical trial results reveal a significant breakthrough in progression-free survival for patients. Presented at the prestigious European Society for Medical Oncology (ESMO) Congress in Berlin, these findings highlight the efficacy of an orally administered combination therapy including giredestrant, a novel selective estrogen receptor degrader (SERD), alongside everolimus, an established mTOR inhibitor. The phase 3 evERA Breast Cancer study marks a distinct progression in targeted therapy for a patient population that has long grappled with treatment resistance and limited options.

Estrogen receptor-positive breast cancers comprise roughly 70% of all breast cancer diagnoses worldwide, representing a sizeable and challenging subgroup due to their inherent potential for developing resistance to endocrine therapies. The clinical landscape is complicated by the emergence of mutations in the estrogen receptor gene (ESR1) that mediate resistance, rendering many standard-of-care regimens ineffective over time. The evERA trial directly addresses this unmet therapeutic need by evaluating whether giredestrant, a next-generation SERD boasting full estrogen receptor antagonism and degradation properties, can overcome these resistance mechanisms when paired with everolimus, itself an inhibitor of a key cancer cell growth pathway.

Unlike earlier SERDs that necessitate monthly intramuscular injections, giredestrant is administered orally, which offers a pronounced advantage in treatment adherence and patient convenience. Mechanistically, giredestrant binds to the estrogen receptor with high specificity, inducing its destabilization and subsequent proteasomal degradation. This action effectively prevents estrogen-driven proliferation signaling in tumor cells, even in settings where ESR1 mutations sustain aberrant receptor activity that compromises the efficacy of conventional endocrine agents. The dual therapeutic approach of combining giredestrant’s receptor-targeting ability with everolimus’s blockade of mTOR—a critical node integrating growth and survival signals—allows for a robust interception of cancer progression pathways.

The evERA study enrolled 373 patients with advanced ER-positive, HER-2-negative breast cancer who were randomized to receive either the all-oral regimen of giredestrant plus everolimus or the standard combination of endocrine therapy plus everolimus. Notably, approximately 55% of the enrolled population presented ESR1 mutations, highlighting the trial’s relevance to a particularly resistant subset. The primary endpoint focused on progression-free survival (PFS), measured both across the entire intention-to-treat cohort and specifically within the ESR1-mutant subgroup, where therapeutic resistance poses the greatest challenge.

After a median follow-up duration of 18.6 months, the results demonstrated a compelling clinical benefit for patients receiving the giredestrant-based regimen. Among individuals harboring ESR1 mutations, median progression-free survival nearly doubled to 9.99 months compared to 5.45 months for those on the standard care arm, representing a 63% relative reduction in the risk of progression or death. This magnitude of improvement clearly establishes the potential of giredestrant to counteract endocrine resistance in a mutation-defined population.

Extending the analysis to the overall intention-to-treat population, encompassing both ESR1-mutant and wild-type tumors, the all-oral combination similarly exhibited a statistically significant increase in median PFS of 8.77 months versus 5.49 months in the comparator group. This 44% reduction in progression risk underscores the therapeutic versatility of giredestrant and supports its broad clinical utility beyond mutation-specific scenarios. These data effectively position the giredestrant-everolimus combination as a pioneering oral regimen that redefines standards of care in metastatic ER-positive breast cancer.

Although overall survival data remain immature, early trends are promising and suggest durable disease control benefits. Moreover, the safety profile observed for the giredestrant and everolimus combination aligns with known adverse event expectations for the individual drugs, demonstrating manageable toxicity and a tolerable regimen for patients. This favorable balance between efficacy and safety is critical for treatment adherence and quality of life considerations in the metastatic setting.

The mechanistic rationale behind the evERA trial stems from the recognition that metastatic ER-positive breast cancers evolve complex resistance pathways. Tumor cells often circumvent single-agent endocrine therapy through ligand-independent activation of the estrogen receptor or downstream signaling alterations via the PI3K/AKT/mTOR axis. By simultaneously degrading the estrogen receptor and inhibiting mTOR, the combination therapy effectively targets two integral and complementary pathways promoting tumor survival and proliferation. This strategic dual inhibition likely underpins the superior clinical outcomes observed.

Historically, therapeutic resistance in ER-positive metastatic breast cancer has posed a formidable barrier, often resulting in disease progression after initial responses to endocrine agents and CDK4/6 inhibitors. The introduction of giredestrant represents a new pharmacologic category capable of overcoming key resistance mechanisms with oral convenience, thereby enhancing treatment sustainability. Its ability to induce complete receptor degradation differentiates it from selective estrogen receptor modulators (SERMs) and earlier SERDs, anchoring its potential to reshape therapeutic paradigms.

The evERA study stands as the first head-to-head, randomized, phase 3 trial evaluating a fully oral SERD-containing regimen against a standard endocrine therapy plus everolimus combination, delivering a novel therapeutic blueprint for prolonged disease control. This milestone marks a paradigm shift by offering an effective, patient-friendly regimen that addresses resistance in late-line metastatic breast cancer settings, where treatment options have historically been limited and the clinical need substantial.

Erica Mayer, MD, MPH, of the Dana-Farber Cancer Institute and the lead investigator of the evERA trial, emphasizes the significance of this advancement. She notes that the combination therapy “is designed to address the most common resistance mechanisms” and “substantially improve disease control,” thereby offering hope for improved survival and quality of life for patients challenged by metastatic ER-positive, HER-2-negative breast cancer. The results underscore the transformational potential of innovative oral therapies that judiciously integrate mechanism-based science with clinical pragmatism.

Funding for this pivotal clinical investigation was provided by F. Hoffmann-La Roche Ltd., reflecting the sustained commitment of industry and academic partnerships toward developing cutting-edge cancer therapeutics. Dana-Farber Cancer Institute, a global leader in oncology research and clinical care, continues to spearhead efforts in translating scientific discovery into tangible patient benefits across the cancer continuum. With this groundbreaking evidence, giredestrant integrated into combination regimens may soon establish a new frontline standard for difficult-to-treat metastatic ER-positive breast cancers, heralding a new era of personalized, effective, and patient-centered cancer therapy.

News Publication Date: October 18, 2025

Web References:
– Dana-Farber Cancer Institute: https://www.dana-farber.org
– European Society for Medical Oncology (ESMO): https://www.esmo.org/meeting-calendar/esmo-congress-2025